3 Things About Vertex Pharmaceuticals That Smart Investors Know
Cystic fibrosis is a deadly lung disease that causes patients to fight for every breath. Hope for a cure appeared on the horizon more than 30 years ago when researchers first isolated the genetic variant causing the disorder. Vertex Pharmaceuticals (NASDAQ: VRTX) delivered on that hope with therapies showing remarkable improvements in lung capacity -- changing the lives of and bringing relief to people with the condition.
In 2019, Vertex introduced Trikafta, a highly effective triple combination of therapies. Total sales for all Vertex products have since grown from $1.7 billion in 2017 to $6.2 billion in 2020. The company finished last year with $6.7 billion in cash, and generated more than $3 billion in free cash flow. With patents that run through 2037, Vertex has set the foundation for an incredibly durable franchise.
Source Fool.com